Peroxisomal fatty acid beta-oxidation in HepG2 cells

Arch Biochem Biophys. 1991 Sep;289(2):329-36. doi: 10.1016/0003-9861(91)90419-j.

Abstract

HepG2 cells, originally derived from a human hepatoblastoma, contain peroxisomes which could be separated from mitochondria and other subcellular organelles by density gradient centrifugation. To determine whether this cell line was a suitable model for human peroxisomal fatty acid beta-oxidation, we investigated the ability of these cells to catabolize very-long-chain fatty acids (VLCFA). HepG2 cell homogenates or digitonin-disrupted cells oxidized both long chain fatty acids and VLCFA, although at somewhat lower rates than human liver homogenates. beta-Oxidation of VLCFA was observed in both peroxisomes and mitochondria of HepG2 cells. Peroxisomal beta-oxidation was independent of carnitine, insensitive to antimycin A and rotenone, and not blocked by an inhibitor of carnitine palmitoyl transferase I. HepG2 peroxisomes contained immunoreactive acyl-CoA oxidase, the first enzyme unique to the peroxisomal beta-oxidation pathway. In addition, HepG2 peroxisomes contained VLCFA-CoA synthetase activity. These results suggest that HepG2 may be a useful model system for the study of human peroxisomal metabolic processes, including beta-oxidation of fatty acids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acyl-CoA Oxidase
  • Antimycin A / pharmacology
  • Carcinoma, Hepatocellular / metabolism
  • Carnitine / metabolism
  • Cell Line
  • Coenzyme A Ligases / metabolism
  • Fatty Acids / metabolism*
  • Humans
  • Liver Neoplasms / metabolism
  • Microbodies / metabolism*
  • Oxidation-Reduction
  • Oxidoreductases / metabolism
  • Subcellular Fractions / metabolism
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / metabolism

Substances

  • Fatty Acids
  • Antimycin A
  • Oxidoreductases
  • Acyl-CoA Oxidase
  • Coenzyme A Ligases
  • Carnitine